GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » Interest Coverage

Pure Biologics (WAR:PUR) Interest Coverage : 0 (At Loss) (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Pure Biologics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Pure Biologics's Operating Income for the three months ended in Sep. 2024 was zł-1.36 Mil. Pure Biologics's Interest Expense for the three months ended in Sep. 2024 was zł-0.31 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Pure Biologics's Interest Coverage or its related term are showing as below:


WAR:PUR's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 150.72
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Pure Biologics Interest Coverage Historical Data

The historical data trend for Pure Biologics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pure Biologics Interest Coverage Chart

Pure Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial - - - - -

Pure Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.35 - - 2.16 -

Competitive Comparison of Pure Biologics's Interest Coverage

For the Biotechnology subindustry, Pure Biologics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pure Biologics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pure Biologics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Pure Biologics's Interest Coverage falls into.



Pure Biologics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pure Biologics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Pure Biologics's Interest Expense was zł-3.83 Mil. Its Operating Income was zł-29.81 Mil. And its Long-Term Debt & Capital Lease Obligation was zł12.85 Mil.

Pure Biologics did not have earnings to cover the interest expense.

Pure Biologics's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Here, for the three months ended in Sep. 2024, Pure Biologics's Interest Expense was zł-0.31 Mil. Its Operating Income was zł-1.36 Mil. And its Long-Term Debt & Capital Lease Obligation was zł0.03 Mil.

Pure Biologics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Pure Biologics  (WAR:PUR) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Pure Biologics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Pure Biologics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Pure Biologics Business Description

Traded in Other Exchanges
N/A
Address
ul. Dunska 11, Wroclaw, POL, 54-427
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Pure Biologics Headlines

No Headlines